Literature DB >> 16343097

Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations.

Diana L Learoyd1, Jessica Gosnell, Marianne S Elston, Tricia J Saurine, Anne-Louise Richardson, Leigh W Delbridge, John V Aglen, Bruce G Robinson.   

Abstract

OBJECTIVE AND
DESIGN: Genetic screening in multiple endocrine neoplasia type 2 (MEN 2) has led to specific management guidelines based on genotype-phenotype analysis. However, there is controversy regarding the appropriate age for prophylactic thyroidectomy in families with mutations in codon 804 in exon 14 of the RET proto-oncogene, where medullary thyroid cancer (MTC) may not develop until adulthood. We prospectively studied two MEN 2A families, one with the V804L and the other with the V804M RET mutation, to report our experience of genetic and biochemical screening and prophylactic thyroidectomy. Family 1 is one of the largest MEN 2A families in the literature, where 22 prophylactic thyroidectomies have been performed. PATIENTS AND
RESULTS: C-cell hyperplasia (CCH) was found in 23 out of 25 thyroidectomy specimens from family members of ages 5 years and upwards. MTC was found in 10 out of 18 adults of age 25 years upwards, including the family 2 proband, who was found to have MTC with lymph node metastases at age 28. Phaeochromocytoma was only observed in one patient, but six cases of histologically confirmed hyperparathyroidism were seen in family 1.
CONCLUSION: We suggest that prophylactic thyroidectomy should not be delayed until adulthood in MEN 2A families carrying codon 804 RET mutations, but should be performed when there is CCH, before the development of MTC, as close as possible to age 6 years, which is the age of the youngest reported case of MTC in '804' families.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16343097     DOI: 10.1111/j.1365-2265.2005.02394.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

1.  Case of Concurrent MTC and PTC in a Patient with a Germline RET Mutation.

Authors:  Kinjal Shah; Mohsen Zena; Edward D Adickes; Robert J Anderson
Journal:  Endocr Pathol       Date:  2015-09       Impact factor: 3.943

Review 2.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

3.  Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations.

Authors:  Thereasa A Rich; Lei Feng; Naifa Busaidy; Gilbert J Cote; Robert F Gagel; Mimi Hu; Camilo Jimenez; Jeffrey E Lee; Nancy Perrier; Steven I Sherman; Steven G Waguespack; Anita Ying; Elizabeth Grubbs
Journal:  Thyroid       Date:  2014-06-06       Impact factor: 6.568

4.  Management of thyroid cancers.

Authors:  Devendra A Chaukar; Anuja D Deshmukh; Mitali R Dandekar
Journal:  Indian J Surg Oncol       Date:  2010-11-21

Review 5.  Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.

Authors:  Samuel A Wells; Furio Pacini; Bruce G Robinson; Massimo Santoro
Journal:  J Clin Endocrinol Metab       Date:  2013-06-06       Impact factor: 5.958

6.  Characterization of V804M-mutated RET proto-oncogene associated with familial medullary thyroid cancer, report of the largest Turkish family.

Authors:  M N Basaran; M M Tuna; E Karakılıç; B A Doğan; N N İmga; D Berker; S Güler
Journal:  J Endocrinol Invest       Date:  2014-12-12       Impact factor: 4.256

7.  How to Assess the Clinical Relevance of Novel RET Missense Variants in the Absence of Functional Studies?

Authors:  Thomas Karrasch; Saskia M Herbst; Ute Hehr; Andreas Schmid; Andreas Schäffler
Journal:  Eur Thyroid J       Date:  2016-02-25

Review 8.  RET and neuroendocrine tumors.

Authors:  Yoshiki Murakumo; Mayumi Jijiwa; Naoya Asai; Masatoshi Ichihara; Masahide Takahashi
Journal:  Pituitary       Date:  2006       Impact factor: 3.599

9.  p.Val804Met, the Most Frequent Pathogenic Mutation in RET, Confers a Very Low Lifetime Risk of Medullary Thyroid Cancer.

Authors:  Chey Loveday; Katherine Josephs; Daniel Chubb; Adam Gunning; Louise Izatt; Marc Tischkowitz; Sian Ellard; Clare Turnbull
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

10.  Unexpected Pathogenic RET p.V804M Variant Leads to the Clinical Diagnosis and Management of Medullary Thyroid Carcinoma.

Authors:  Arezou A Ghazani; Katelyn M Breen; Meaghan Dwan; Justine A Barletta; Donna R Vatnick; Samantha M Stokes; Caroline Block; Gerard M Doherty; Aviva Y Cohn; Ellen Marqusee; Judy E Garber; Huma Q Rana
Journal:  Am J Case Rep       Date:  2020-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.